Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase I Dose Escalation Study of Topotecan and Pazopanib in Children With Recurrent/Refractory Solid Tumours (TOPAZ)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02303028
Recruitment Status : Active, not recruiting
First Posted : November 27, 2014
Last Update Posted : March 18, 2020
Sponsor:
Collaborator:
C17 Council
Information provided by (Responsible Party):
Jim Whitlock, The Hospital for Sick Children

Brief Summary:
This is a phase I, dose escalation study where topotecan will be administered at lower doses given more frequently on a prolonged schedule (low dose metronomic; LDM), in combination with pazopanib administered in a specific dose range. The maximum tolerated dose (MTD) and the recommended phase 2 dose (RP2D) will be evaluated for LDM topotecan in combination with pazopanib in children with recurrent or refractory solid tumours. Pharmacokinetic and pharmacodynamic studies will be conducted to further define the exposure to and activity of LDM topotecan in combination with pazopanib.

Condition or disease Intervention/treatment Phase
Solid Tumors Drug: Topotecan and Pazopanib Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 66 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I and Enrichment Study of Low-dose Metronomic Topotecan and Pazopanib in Pediatric Patients With Recurrent or Refractory Solid Tumours
Study Start Date : March 2015
Estimated Primary Completion Date : July 2020
Estimated Study Completion Date : December 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Topotecan and Pazopanib
Low dose Topotecan will be given metronomically in combination with Pazopanib at the dose level assigned at study entry
Drug: Topotecan and Pazopanib
Low-dose metronomic Topotecan and Pazopanib will be escalated as per the dose escalation schema.
Other Names:
  • Hycamtin
  • Votrient




Primary Outcome Measures :
  1. Maximum tolerated dose (MTD) of low dose metronomic (LDM)Topotecan [ Time Frame: Dose limiting toxicities (DLT) will be identified during the first cycle of therapy (28 days) ]
    MTD is dependent on the number of subjects who experience a DLT at a given dose level

  2. Recommended phase 2 dose (RP2D) of LDM Topotecan [ Time Frame: Dose limiting toxicities (DLT) will be identified during the first cycle of therapy (28 days) ]
    The RP2D will be defined as the highest dose, at or below the MTD, at which the median number of cycles tolerated by subjects is ≥ 3.


Secondary Outcome Measures :
  1. Anti-tumour activity of LDM Topotecan in combination with Pazopanib [ Time Frame: 24 months ]
    To preliminarily define the anti-tumour activity of LDM Topotecan in combination with pazopanib in pediatric solid tumours within the confines of a phase 1 study, and more specifically in cohorts of children with i) neuroblastoma and ii) rhabdomyosarcoma

  2. Pharmacokinetics of LDM Topotecan and Pazopanib [ Time Frame: 24 months ]
    To characterize the pharmacokinetics of LDM Topotecan and Pazopanib, as well as any drug-drug interactions

  3. Anti-angiogenic activity of LDM Topotecan and Pazopanib [ Time Frame: 24 months ]
    To assess the anti-angiogenic activity of this regimen by evaluating changes in plasma cytokines and angiogenic factors (CAF).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   2 Years to 21 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

INCLUSION:

  1. Disease: Part 1-Relapsed or refractory solid tumours with histological verification of malignancy. Patients with CNS tumours are not eligible. Parts 2A and 2B - histological verification of one of the following solid tumours: Neuroblastoma or Rhabdomyosarcoma
  2. Measurable or evaluable disease
  3. No known curative therapy, or therapy proven to prolong survival with an acceptable QOL
  4. Performance status: Lansky or Karnofsky ≥ 50%
  5. ORGAN FUNCTION CRITERIA Bone Marrow Function

    • Peripheral ANC ≥ 1.5x109/L; Plt ≥ 100x109/L and Hgb ≥ 80 g/L (RBC transfusion permitted) Renal Function
    • Measured creatinine clearance or radioisotope GFR ≥ 70 mL/min/1.73 m2, OR a serum creatinine based on age/gender that meets the criteria outlined in the protocol
    • Urinalysis negative for protein, urine protein:creatinine ratio of ≤ 1, OR a 24-hour urine protein < 1000 mg/dL
    • <Gr.1 abnormalities of K, Ca (confirmed by ionized Ca),Mg or Ph (supplementation allowed) Liver Function
    • Total serum bilirubin ≤ 1.5xULN for age
    • SGPT (ALT) ≤ 2.5 x ULN and SGOT (AST) ≤ 2.5 x ULN
    • Serum albumin ≥ 20 g/L Cardiac Function
    • Adequate systolic ventricular function (LVSF≥ 27% or LVEF ≥ 50%)
    • QTc measured by ECG must be < 450 msec.
    • No history of MI, severe or unstable angina, peripheral vascular disease, or familial QTc prolongation Blood Pressure
    • Blood pressure ≤ 95th percentile for age, height, gender AND one of:
    • No current anti-hypertensive therapy, OR on stable doses of no more than one anti-hypertensive medication CNS Function
    • Subjects with known history of seizures must have well-controlled seizures and not receiving enzyme-inducing anti-convulsants Coagulation Function
    • INR ≤ 1.2 and PTT ≤ 1.2xULN
  6. Prior Therapy

    • Myelosuppressive chemo must not have been given within 3 weeks of study enrolment (6 weeks if nitrosourea)
    • At least 7 days must have elapsed since completion of therapy with a growth factor that supports platelet or white cell number or function. At least 14 days must have elapsed after receiving pegfilgrastim.
    • Biologic anti-neoplastic agent (including VEGF-blocking TKI) must not have been administered within 7 days of study enrolment
    • At least 3 half lives of the monoclonal antibody must have elapsed since the last dose administered
    • ≥ 2 weeks must have elapsed since local palliative XRT (small port); > 13 weeks since prior total body irradiation (TBI), craniospinal XRT or > 50% radiation of pelvis; or > 6 weeks if other substantial bone marrow irradiation
    • ≥ 8 weeks must have elapsed since MIBG therapy for neuroblastoma
    • At least 60 days must have elapsed from autologous or allogeneic stem cell transplant with no signs of GVHD.
    • At least 28 days from major surgery and wounds must be healed. At least 7 days from open and/or core biopsy.
  7. Ability to take liquid medication by mouth

EXCLUSION:

  1. Patients with CNS tumours or known CNS metastases
  2. Pregnancy, breast feeding, or unwillingness to use effective contraception during the study
  3. Subjects currently receiving:

    • Corticosteroids who haven't been on a stable or decreasing dose of corticosteroid for 7 days prior
    • Another investigational drug; other anti-cancer agents or radiation therapy
    • More than one medication for blood pressure control
    • Therapeutic anticoagulation, including systemic use of warfarin, heparin, or low molecular weight heparin at any dose
    • Aspirin, and/or ibuprofen, or other NSAIDs
    • Drugs metabolized through several of the specific P450 cytochrome isoforms and those receiving drugs with a known risk of torsades de pointes
    • Subjects who require thyroid replacement therapy are not eligible if they have not been receiving a stable replacement dose for at least 4 weeks prior to study enrolment.
  4. Subjects who have an uncontrolled infection or serious non-healing would, ulcer or bone fracture.
  5. Evidence of active bleeding, intratumoral haemorrhage, or bleeding diathesis, hemoptysis or any evidence of GI hemorrhage.
  6. History (within 26 weeks prior to study enrolment) of arterial thromboembolic events (including TIA, CVA, or MI), pulmonary embolism, DVT or other venous thromboembolic event.
  7. Evidence of tumour-related or other thrombus at time of enrolment
  8. Major surgical procedure, laparoscopic procedure or significant traumatic injury within 28 days prior to Day 1 therapy. Open or core biopsy within 7 days prior to Day 1 of therapy. Fine needle aspirate within 48 hours prior to Day 1 therapy.
  9. Previous, documented hypersensitivity reactions to topotecan or pazopanib
  10. History of abdominal fistula, GI perforation, or intra-abdominal abscess within 28 days of study enrolment.
  11. QTc > 450msec on baseline ECG or history of familial prolonged QTc syndrome
  12. History of inflammatory lung disease secondary to exposure to mTOR or tyrosine kinase inhibitors.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02303028


Locations
Layout table for location information
Canada, Alberta
Alberta Children's Hospital
Calgary, Alberta, Canada
Canada, British Columbia
BC Children's Hospital
Vancouver, British Columbia, Canada
Canada, Manitoba
CancerCare Manitoba
Winnipeg, Manitoba, Canada
Canada, Newfoundland and Labrador
Janeway Child Health Centre
Saint John's, Newfoundland and Labrador, Canada
Canada, Nova Scotia
IWK Health Centre
Halifax, Nova Scotia, Canada
Canada, Ontario
McMaster Children's Hospital
Hamilton, Ontario, Canada
Children's Hospital, London Health Sciences Centre
London, Ontario, Canada
Children's Hospital of Eastern Ontario (CHEO)
Ottawa, Ontario, Canada
Hospital for Sick Children
Toronto, Ontario, Canada
Canada, Quebec
CHU St. Justine Hopital
Montreal, Quebec, Canada
Sponsors and Collaborators
The Hospital for Sick Children
C17 Council
Investigators
Layout table for investigator information
Study Chair: Jim Whitlock The Hospital for Sick Children
Layout table for additonal information
Responsible Party: Jim Whitlock, Chief, Division of Haematology/Oncology, The Hospital for Sick Children
ClinicalTrials.gov Identifier: NCT02303028    
Other Study ID Numbers: 1000046233
IND.217 ( Other Identifier: NCIC CTG )
First Posted: November 27, 2014    Key Record Dates
Last Update Posted: March 18, 2020
Last Verified: March 2020
Keywords provided by Jim Whitlock, The Hospital for Sick Children:
Pediatric
Solid Tumour
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms
Topotecan
Topoisomerase I Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents